Advisory Board

Dr. Greenberg is Director, Alzheimer's Disease Translational Center at Johns Hopkins University School of Medicine. He previously served as Director of Strategy for the Toronto Dementia Research Alliance. He previously held positions in management and science at a number of companies involved in Alzheimer’s research including Bellus Health, AstraZeneca Pharmaceuticals, Cephalon, Inc., The Upjohn Company and California Biotechnology, Inc. Dr. Greenberg has authored or co-authored over 70 articles in peer-reviewed journals and 19 book chapters and reviews.

Dr. Kopia is currently a freelance consultant to the pharmaceutical and medical device industry. Previously, he worked for many years at Johnson and Johnson Cordis and there was a Research Fellow. During his tenure at Johnson and Johnson, he was awarded the Johnson Medal for his accomplishments in the development of coated stents. From 1989 to 1995,he held the position of Director of Pharmacology at Zynaxis, Inc.

Dr. Metcalf has served as the Chief Scientific Officer of Global Blood Therapeutics and Executive Vice President and Head of Drug Discovery of Incyte Corporation. During the majority of his distinguished career in industry, Dr. Metcalf worked at SmithKline Beecham and rose to the position of Sr. Vice President, Discovery Chemistry & Platform Technology. Brian also had previously served as Senior Vice President and CSO of Kosan Biosciences (2000-2002). He currently serves on the Scientific Advisory Boards of Maze, Global Blood Therapeutics, Prelude, and BridgeBio.

Dr. Robertson, a Canada Research Chair in Amyotrophic Lateral Sclerosis and a Ontario Premier Research Excellence award, is Professor at the Tanz Centre for Research in Neurodegenerative Diseases and of the Department of Laboratory Medicine and Pathology, University of Toronto. She uses multidisciplinary approaches to elucidate the molecular mechanisms of ALS, across the continuum of in vivo, ex vivo, and in vivo disease models. Dr. Robertson obtained her Ph.D. studying Alzheimer's disease at Kings College, London and is a past recipient of fellowships from the Wellcome Trust, the UK Motor Neurone Disease Association, and the American ALS Association.

Dr. Shannon currently serves as a consultant to the pharmaceutical industry specializing in late-stage pharmaceutical development and regulatory strategy. In his last two positions in the industry Dr. Shannon served as Sr. Director, Project Management, OSI Pharmaceuticals from 2003 to 2006 and as Sr. Director, Pharmaceutical Development, Ilex Pharmaceuticals from 2001 to 2003.